Ironwood Pharmaceuticals, Inc. (IRWD) News
Follow Ironwood Pharmaceuticals, Inc. (IRWD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Ironwood Pharmaceuticals to participate in Wells Fargo healthcare conference fireside chat
Ironwood Pharmaceuticals will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10 at 10:15 a.m. ET. A live webcast will be available via Investors & Media.
EQUITY | Sep 03, 2026, 08:05 PM UTC
L
Ironwood Pharmaceuticals Raises FY2026 Sales Guidance from $450.000M-$475.000M to $460.000M-$485.000M vs $460.118M Est
Ironwood Pharmaceuticals (NASDAQ: IRWD ) raises FY2026 sales outlook from $450.000 million-$475.000 million to $460.000 million-$485.000 million vs $460.118 million estimate.
EARNINGS | Aug 06, 2026, 11:09 AM UTC
L
IRWD Ironwood appoints Dr. Jeffrey silber chief Medical officer and head of research and drug development; stars-2 trial initiated in June a
IRWD Ironwood appoints Dr. Jeffrey silber chief Medical officer and head of research and drug development; stars-2 trial initiated in June and is now actively recruiting patients Ironwood Pharmaceuticals - initiates phas
EQUITY | Jul 14, 2026, 11:31 AM UTC